Resectable pancreatic ductal adenocarcinoma · Data

technologies

Biliary stenting and drainage CT (computed tomography)Cytotoxic chemotherapy Endoscopic ultrasound and EBUS systems Enhanced recovery (ERAS) and perioperative nutrition Germline (hereditary) testing High-risk pancreatic surveillance (CAPS / PRECEDE)Immune checkpoint inhibitors Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)KRAS & RAS inhibitors Liquid biopsy (ctDNA)MRD / molecular residual disease testing Nutrition support and cachexia management Off-the-shelf cancer vaccines Personalised neoantigen (mRNA) vaccines Platinum agents Robotic & minimally invasive surgery Topoisomerase-I inhibitors (and ADC payloads)

targets

BRCA1 / BRCA2 (HRD)KRAS PD-L1

drugs

ApprovedMonoclonal antibody (anti-PD-L1)

Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)

Phase 2Personalised mRNA neoantigen vaccine

Autogene cevumeran

ApprovedOral fluoropyrimidine prodrug (antimetabolite)

Capecitabine · Xeloda

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

Phase 2Off-the-shelf lymph-node-targeted KRAS peptide vaccine

ELI-002 7P

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedNucleoside analogue (deoxycytidine)

Gemcitabine · Gemzar / Infugem

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

EstablishedOral porcine pancreatic enzymes (lipase, protease, amylase) in enteric-coated capsules

Pancrelipase (pancreatic enzyme replacement therapy) · Creon, Nutrizym, Pancrease

ApprovedOral fluoropyrimidine combination (antimetabolite)

Tegafur, gimeracil and oteracil (S-1) · Teysuno

trials

roadmaps

Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question

ideas

Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed Four weeks of training and nutrition before major cancer surgery, as standard Personalised vaccines given only when the blood test turns positive RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable

people

Eileen M. O'Reilly Jürgen Weitz Marc G. Besselink Paula Ghaneh Richard Schulick Thierry Conroy Vinod P. Balachandran

key papers

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma Burris 1997: gemcitabine becomes the first standard treatment for advanced pancreatic cancer Circulating tumor DNA as a clinical test in resected pancreatic cancer Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers CONKO-001: adjuvant gemcitabine and long-term outcomes after resected pancreatic cancer Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma ESPAC-3: adjuvant fluorouracil plus folinic acid versus gemcitabine after pancreatic cancer resection ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial NORPACT-1: neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial Preservation of the pylorus in pancreaticoduodenectomy PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival Treatment of carcinoma of the ampulla of Vater

biomarkers

ctDNA MRD positivity (molecular residual disease after curative treatment)

DataResectable pancreatic ductal adenocarcinoma

Data

Related pages

Similar pages

technologies

targets

drugs

companies

pathways

terms

trials

roadmaps

ideas

people

key papers

biomarkers

Machine-readable versions

DataResectable pancreatic ductal adenocarcinoma

Data

Related pages

Similar pages

technologies

targets

drugs

companies

pathways

terms

trials

roadmaps

ideas

people

key papers

biomarkers

Machine-readable versions